{"status": "Ok", "redirect_url": "https://www.businesswire.com/news/home/20260602237640/en/Gilead%E2%80%99s-Livdelzi%C2%AE-Seladelpar-Delivers-Statistically-Significant-Composite-ALP-Normalization-in-Phase-3-IDEAL-Trial-in-Primary-Biliary-Cholangitis-PBC", "message": "News view counter 773293 successfully enlarged"}